Abstract CS1-1: The genomics of metastatic breast cancer: What are we learning?

Abstract

Abstract Over the past decade, genomic characterization of tumors from cancer patients obtained through large-scale sequencing projects has shed enormous light on the molecular underpinnings of cancer. These discoveries have, in turn, led to the development of novel therapies and preventive measures that have already revolutionized cancer care. Despite this tremendous progress, our understanding of the genomics of metastatic breast cancer – and in particular cancers that have developed resistance to therapies – remains incomplete. In this presentation, we will discuss recent and ongoing studies that focus on the genomics of metastatic breast cancer, and how the learnings from these studies are influencing precision medicine strategies for patients with advanced breast cancer. We will focus on how genomic and molecular characterization of metastatic tumor samples from patients can shed light on the biology of metastatic breast cancer and can enable the development of strategies to overcome or prevent drug resistance. We will discuss the landscape of mutations in metastatic breast cancer, the potential clinical impact of genomic profiling, and the incorporation of genomic information into clinical care and clinical trials. We will also discuss how partnering directly with patients, in projects such as The Metastatic Breast Cancer Project (mbcproject.org), enables rapid identification of large numbers of patients willing to share tumors, saliva, and medical records to accelerate this research. Citation Format: Wagle N. The genomics of metastatic breast cancer: What are we learning? [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr CS1-1.